Top

Published in:

01-06-2012 | Preclinical study

Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells

Authors: M. Luísa Dória, Zita Cotrim, Bárbara Macedo, Cláudia Simões, Pedro Domingues, Luisa Helguero, M. Rosário Domingues

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Abstract

Breast cancer is the leading cause of cancer-related deaths in women. Altered cellular functions of cancer cells lead to uncontrolled cellular growth and morphological changes. Cellular biomembranes are intimately involved in the regulation of cell signaling; however, they remain largely understudied. Phospholipids (PLs) are the main constituents of biological membranes and play important functional, structural and metabolic roles. The aim of this study was to establish if patterns in the PL profiles of mammary epithelial cells and breast cancer cells differ in relation to degree of differentiation and metastatic potential. For this purpose, PLs were analyzed using a lipidomic approach. In brief, PLs were extracted using Bligh and Dyer method, followed by a separation of PL classes by thin layer chromatography, and subsequent analysis by mass spectrometry (MS). Differences and similarities were found in the relative levels of PL content between mammary epithelial and breast cancer cells and between breast cancer cells with different levels of aggressiveness. When compared to the total PL content, phosphatidylcholine levels were reduced and lysophosphatydilcholines increased in the more aggressive cancer cells; while phosphatidylserine levels remained unchanged. MS analysis showed alterations in the classes of phosphatidylcholine, lysophosphatidylcholine, sphingomyelin, and phosphatidylinositides. In particular, the phosphatidylinositides, which are signaling molecules that affect proliferation, survival, and migration, showed dramatic alterations in their profile, where an increase of phosphatdylinositides saturated fatty acids chains and a decrease in C20 fatty acids in cancer cells compared with mammary epithelial cells was observed. At present, information about PL changes in cancer progression is lacking. Therefore, these data will be useful as a starting point to define possible PLs with prospective as biomarkers and disclose metabolic pathways with potential for therapy.

Available only for authorised users

Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150. doi:10.1200/JCO.2005.05.2308 PubMedCrossRef

Fernandis AZ, Wenk MR (2009) Lipid-based biomarkers for cancer. J Chromatogr B Analyt Technol Biomed Life Sci 877(26):2830–2835. doi:10.1016/j.jchromb.2009.06.015 PubMedCrossRef

Escriba PV, Gonzalez-Ros JM, Goni FM, Kinnunen PK, Vigh L, Sanchez-Magraner L, Fernandez AM, Busquets X, Horvath I, Barcelo-Coblijn G (2008) Membranes: a meeting point for lipids, proteins and therapies. J Cell Mol Med 12(3):829–875. doi:10.1111/j.1582-4934.2008.00281.x PubMedCrossRef

Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH Jr, Murphy RC, Raetz CR, Russell DW, Seyama Y, Shaw W, Shimizu T, Spener F, van Meer G, VanNieuwenhze MS, White SH, Witztum JL, Dennis EA (2005) A comprehensive classification system for lipids. J Lipid Res 46(5):839–861. doi:10.1194/jlr.E400004-JLR200 PubMedCrossRef

van Meer G, de Kroon AI (2011) Lipid map of the mammalian cell. J Cell Sci 124(Pt 1):5–8. doi:10.1242/jcs.071233 PubMedCrossRef

Wymann MP, Schneiter R (2008) Lipid signalling in disease. Nat Rev Mol Cell Biol 9(2):162–176. doi:10.1038/nrm2335 PubMedCrossRef

Patra SK (2008) Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta Rev Cancer 1785(2):182–206. doi:10.1016/j.bbcan.2007.11.002

Ackerstaff E, Glunde K, Bhujwalla ZM (2003) Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 90(3):525–533. doi:10.1002/jcb.10659 PubMedCrossRef

Di Paolo G, De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443(7112):651–657. doi:10.1038/nature05185 PubMedCrossRef

10.

Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, Huang S (2004) Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 64(12):4209–4217. doi:10.1158/0008-5472.CAN-04-0060 PubMedCrossRef

11.

Causeret M, Taulet N, Comunale F, Favard C, Gauthier-Rouviere C (2005) N-cadherin association with lipid rafts regulates its dynamic assembly at cell–cell junctions in C2C12 myoblasts. Mol Biol Cell 16(5):2168–2180. doi:10.1091/mbc.E04-09-0829 PubMedCrossRef

12.

Patra SK (2008) Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 1785(2):182–206. doi:10.1016/j.bbcan.2007.11.002 PubMed

13.

Paschos KA, Canovas D, Bird NC (2009) The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 21(5):665–674. doi:10.1016/j.cellsig.2009.01.006 PubMedCrossRef

14.

Merchant TE, Kasimos JN, Vroom T, de Bree E, Iwata JL, de Graaf PW, Glonek T (2002) Malignant breast tumor phospholipid profiles using P-31 magnetic resonance. Cancer Lett 176(2):159–167PubMedCrossRef

15.

Merchant TE, Meneses P, Gierke LW, Den Otter W, Glonek T (1991) 31P magnetic resonance phospholipid profiles of neoplastic human breast tissues. Br J Cancer 63(5):693–698PubMedCrossRef

16.

Zehethofer N, Pinto DM (2008) Recent developments in tandem mass spectrometry for lipidomic analysis. Anal Chim Acta 627(1):62–70. doi:10.1016/j.aca.2008.06.045 PubMedCrossRef

17.

Watson AD (2006) Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res 47(10):2101–2111. doi:10.1194/jlr.R600022-JLR200 PubMedCrossRef

18.

Pulfer M, Murphy RC (2003) Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev 22(5):332–364. doi:10.1002/mas.10061 PubMedCrossRef

19.

Dill AL, Ifa DR, Manicke NE, Costa AB, Ramos-Vara JA, Knapp DW, Cooks RG (2009) Lipid profiles of canine invasive transitional cell carcinoma of the urinary bladder and adjacent normal tissue by desorption electrospray ionization imaging mass spectrometry. Anal Chem 81(21):8758–8764. doi:10.1021/ac901028b PubMedCrossRef

20.

Kim Y, Shanta SR, Zhou LH, Kim KP (2010) Mass spectrometry based cellular phosphoinositides profiling and phospholipid analysis: a brief review. Exp Mol Med 42(1):1–11. doi:10.3858/emm.2010.42.1.001 PubMedCrossRef

21.

Kim H, Min HK, Kong G, Moon MH (2009) Quantitative analysis of phosphatidylcholines and phosphatidylethanolamines in urine of patients with breast cancer by nanoflow liquid chromatography/tandem mass spectrometry. Anal Bioanal Chem 393(6–7):1649–1656. doi:10.1007/s00216-009-2621-3 PubMedCrossRef

22.

Min HK, Kong G, Moon MH (2010) Quantitative analysis of urinary phospholipids found in patients with breast cancer by nanoflow liquid chromatography-tandem mass spectrometry: II. Negative ion mode analysis of four phospholipid classes. Anal Bioanal Chem 396(3):1273–1280. doi:10.1007/s00216-009-3292-9 PubMedCrossRef

23.

Reichmann E, Schwarz H, Deiner EM, Leitner I, Eilers M, Berger J, Busslinger M, Beug H (1992) Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 71(7):1103–1116PubMedCrossRef

24.

Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA (2001) Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61(1):293–302PubMed

25.

Blixt Y, Valeur A, Everitt E (1990) Cultivation of HeLa cells with fetal bovine serum or Ultroser G: effects on the plasma membrane constitution. In Vitro Cell Dev Biol 26(7):691–700PubMedCrossRef

26.

Elliott WM, Auersperg N (1993) Growth of normal human ovarian surface epithelial cells in reduced-serum and serum-free media. In Vitro Cell Dev Biol 29A(1):9–18PubMedCrossRef

27.

Spence MW, Byers DM, Palmer FB, Cook HW (1989) A new Zn2+-stimulated sphingomyelinase in fetal bovine serum. J Biol Chem 264(10):5358–5363PubMed

28.

Warden CH, Friedkin M (1984) Regulation of phosphatidylcholine biosynthesis by mitogenic growth factors. Biochim Biophys Acta 792(3):270–280PubMed

29.

Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37(8):911–917PubMedCrossRef

30.

Zhou X, Arthur G (1992) Improved procedures for the determination of lipid phosphorus by malachite green. J Lipid Res 33(8):1233–1236PubMed

31.

Fuchs B, Suss R, Teuber K, Eibisch M, Schiller J (2011) Lipid analysis by thin-layer chromatography—a review of the current state. J Chromatogr A 1218(19):2754–2774. doi:10.1016/j.chroma.2010.11.066 PubMedCrossRef

32.

Koivusalo M, Haimi P, Heikinheimo L, Kostiainen R, Somerharju P (2001) Quantitative determination of phospholipid compositions by ESI-MS: effects of acyl chain length, unsaturation, and lipid concentration on instrument response. J Lipid Res 42(4):663–672PubMed

33.

Sterin M, Cohen JS, Ringel I (2004) Hormone sensitivity is reflected in the phospholipid profiles of breast cancer cell lines. Breast Cancer Res Treat 87(1):1–11PubMedCrossRef

34.

Han X, Gross RW (2005) Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 24(3):367–412. doi:10.1002/mas.20023 PubMedCrossRef

35.

Hsu FF, Turk J (2009) Electrospray ionization with low-energy collisionally activated dissociation tandem mass spectrometry of glycerophospholipids: mechanisms of fragmentation and structural characterization. J Chromatogr B Analyt Technol Biomed Life Sci 877(26):2673–2695. doi:10.1016/j.jchromb.2009.02.033 PubMedCrossRef

36.

Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H (2002) Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 62(7):1966–1970PubMed

37.

Olayioye MA, Vehring S, Muller P, Herrmann A, Schiller J, Thiele C, Lindeman GJ, Visvader JE, Pomorski T (2005) StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein. J Biol Chem 280(29):27436–27442. doi:10.1074/jbc.M413330200 PubMedCrossRef

38.

Hoffmann P, Olayioye MA, Moritz RL, Lindeman GJ, Visvader JE, Simpson RJ, Kemp BE (2005) Breast cancer protein StarD10 identified by three-dimensional separation using free-flow electrophoresis, reversed-phase high-performance liquid chromatography, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis 26(6):1029–1037. doi:10.1002/elps.200406197 PubMedCrossRef

39.

Murphy NC, Biankin AV, Millar EK, McNeil CM, O’Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, Henshall SM, Visvader JE, Sutherland RL (2010) Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. Int J Cancer 126(6):1445–1453. doi:10.1002/ijc.24826 PubMed

40.

Murakami M, Kudo I (2002) Phospholipase A2. J Biochem 131(3):285–292PubMedCrossRef

41.

Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K, Ogawa M (1993) Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer 71(10):3058–3064PubMedCrossRef

42.

Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158(2):227–233. doi:10.1083/jcb.200204026 PubMedCrossRef

43.

Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K (2002) Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277(42):39436–39442. doi:10.1074/jbc.M205623200 PubMedCrossRef

44.

Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW, Lee HY (2002) Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19(7):603–608PubMedCrossRef

45.

Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G (1998) Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280(8):719–723PubMedCrossRef

46.

Ogretmen B (2006) Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 580(23):5467–5476. doi:10.1016/j.febslet.2006.08.052 PubMedCrossRef

47.

Hsu FF, Turk J (2000) Structural determination of sphingomyelin by tandem mass spectrometry with electrospray ionization. J Am Soc Mass Spectrom 11(5):437–449PubMedCrossRef

48.

Koyanagi S, Kuga M, Soeda S, Hosoda Y, Yokomatsu T, Takechi H, Akiyama T, Shibuya S, Shimeno H (2003) Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int J Cancer 105(1):1–6. doi:10.1002/ijc.11024 PubMedCrossRef

49.

Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS (2002) Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res 62(21):6312–6317PubMed

50.

Seijo L, Merchant TE, van der Ven LT, Minsky BD, Glonek T (1994) Meningioma phospholipid profiles measured by 31P nuclear magnetic resonance spectroscopy. Lipids 29(5):359–364PubMedCrossRef

51.

Vance JE, Steenbergen R (2005) Metabolism and functions of phosphatidylserine. Prog Lipid Res 44(4):207–234. doi:10.1016/j.plipres.2005.05.001 PubMedCrossRef

52.

Shi J, Pipe SW, Rasmussen JT, Heegaard CW, Gilbert GE (2008) Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure. J Thromb Haemost 6(7):1167–1174. doi:10.1111/j.1538-7836.2008.03010.x PubMedCrossRef

53.

Wolfs JL, Comfurius P, Rasmussen JT, Keuren JF, Lindhout T, Zwaal RF, Bevers EM (2005) Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 62(13):1514–1525. doi:10.1007/s00018-005-5099-y PubMedCrossRef

54.

Stace CL, Ktistakis NT (2006) Phosphatidic acid- and phosphatidylserine-binding proteins. Biochim Biophys Acta 1761(8):913–926. doi:10.1016/j.bbalip.2006.03.006 PubMed

55.

Yeung T, Gilbert GE, Shi J, Silvius J, Kapus A, Grinstein S (2008) Membrane phosphatidylserine regulates surface charge and protein localization. Science 319(5860):210–213. doi:10.1126/science.1152066 PubMedCrossRef

56.

Dobrzynska I, Szachowicz-Petelska B, Sulkowski S, Figaszewski Z (2005) Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol Cell Biochem 276(1–2):113–119. doi:10.1007/s11010-005-3557-3 PubMedCrossRef

57.

Jiang BH, Liu LZ (2008) PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784(1):150–158. doi:10.1016/j.bbapap.2007.09.008 PubMed

58.

Larijani B, Dufourc EJ (2006) Polyunsaturated phosphatidylinositol and diacylglycerol substantially modify the fluidity and polymorphism of biomembranes: a solid-state deuterium NMR study. Lipids 41(10):925–932PubMedCrossRef

Title: Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells
Authors: M. Luísa Dória
Zita Cotrim
Bárbara Macedo
Cláudia Simões
Pedro Domingues
Luisa Helguero
M. Rosário Domingues
Publication date: 01-06-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1823-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results

Vascular proliferation is a prognostic factor in breast cancer

The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin

Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence

The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians

Improving communication of breast cancer recurrence risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer